NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
P/E ratio for NRx Pharmaceuticals, Inc. (NRXP)
P/E ratio as of 2023: -1.16
According to NRx Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.16. At the end of 2022 the company had a P/E ratio of -20.72.
P/E ratio history for NRx Pharmaceuticals, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.16 |
| 2022 | -20.72 |
| 2021 | -31.27 |
| 2020 | -677.26 |
| 2019 | 132.06 |
| 2018 | 1377.20 |
| 2017 | -83.27 |